Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.

Item
http://www.wikidata.org/entity/Q36498695
A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes MellitusEfficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Exenatide extended-release; clinical trials, patient preference, and economic considerations.Long-acting preparations of exenatideIncretin-based therapies: focus on effects beyond glycemic control alone.Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment.Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes.Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonistsRationale for treatment options for mealtime glucose control in patients with type 2 diabetes.Exenatide once weekly improved 24-hour glucose control and reduced glycemic variability in metformin-treated patients with type 2 diabetes: a randomized, placebo-controlled trial.A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes.Effects of exenatide twice daily, exenatide once weekly or insulin in patients with type 2 diabetes and baseline HbA1c ≥10.0%: Two pooled analyses including 20 randomised controlled trials.
P2860

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.

Item
http://www.wikidata.org/entity/Q36498695
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Comparison of safety and toler ...... patients with type 2 diabetes.
@ast
Comparison of safety and toler ...... patients with type 2 diabetes.
@en
type
label
Comparison of safety and toler ...... patients with type 2 diabetes.
@ast
Comparison of safety and toler ...... patients with type 2 diabetes.
@en
prefLabel
Comparison of safety and toler ...... patients with type 2 diabetes.
@ast
Comparison of safety and toler ...... patients with type 2 diabetes.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Comparison of safety and toler ...... patients with type 2 diabetes.
@en
P2093
P2860
P304
P31
P356
10.1111/J.1463-1326.2012.01639.X
P433
P478
P577
P5875
P698
P921
P932